Drug companies racing to develop Covid treatments face an uphill battle to create the billions of doses that will likely be needed. It's a production push the likes of which the industry has never seen before.
NECI's Jenn Azar & Phil Braun discuss the need for automation.Â
Read Full Article By Allison DeAngelis, Life Sciences Reporter of the Boston Business Journal